Acceleron recently announced plans to expand its pipeline into a new therapeutic area; pulmonary disease, with a first indication in pulmonary arterial hypertension (PAH), a rare, progressive and life-threatening blood vessel disorder. The Company anticipates beginning a Phase 2 trial in sotatercept in PAH in the first half of 2018.
Results from a preclinical trial with sotatercept in PAH demonstrated superior results to standard of care (vasodilators), showing the product candidate’s potential to be a disease-modifying therapy.
|Pulmonary Arterial Hypertension|
Pulmonary Arterial Hypertension
Ph2 Trial (Planned)Ph2 Trial
Pulmonary arterial hypertension (PAH) occurs when pulmonary arteries thicken or become rigid, making blood flow more difficult. This causes the heart to work harder to push blood through the arteries, which are no longer able to carry adequate blood to the lungs. As a result, the body doesn’t get the oxygen it needs which causes shortness of breath, chest pain, dizziness, fainting, swelling in arms and legs (edema), chest pressure or pain (angina), and racing pulse.
There is no cure for PAH and often the life expectancy of a PAH patient is between 5-7 years after diagnosis despite a combination of lifestyle changes, medicines (vasodilators), and surgeries which may alter the progression of the disease. Within years, everyday activities such as walking and showering, will eventually become impossible and many patients will require supplementary oxygen.
Based on preclinical results, we believe that sotatercept could be a disease- modifying therapy for PAH. We recently announced that we gained rights for pulmonary indications from Celgene for sotatercept. We plan to initiate a Phase 2 trial in PAH in the first half of 2018.